158 related articles for article (PubMed ID: 33450077)
1. Over-expression of stromal periostin correlates with poor prognosis of cutaneous squamous cell carcinomas.
Lincoln V; Chao L; Woodley DT; Murrell D; Kim M; O'Toole EA; Ly A; Cogan J; Mosallaei D; Wysong A; Chen M
Exp Dermatol; 2021 May; 30(5):698-704. PubMed ID: 33450077
[TBL] [Abstract][Full Text] [Related]
2. Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas.
Föll MC; Fahrner M; Gretzmeier C; Thoma K; Biniossek ML; Kiritsi D; Meiss F; Schilling O; Nyström A; Kern JS
Matrix Biol; 2018 Mar; 66():1-21. PubMed ID: 29158163
[TBL] [Abstract][Full Text] [Related]
3. Immune Disregulation in Cutaneous Squamous Cell Carcinoma of Patients with Recessive Dystrophic Epidermolysis Bullosa: A Single Pilot Study.
Filoni A; Cicco G; Cazzato G; Bosco A; Lospalluti L; Tucci M; Cimmino A; Foti C; Marzullo A; Bonamonte D
Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207500
[TBL] [Abstract][Full Text] [Related]
4. Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases.
Hwang A; Kwon A; Miller CH; Reimer-Taschenbrecker A; Paller AS
Orphanet J Rare Dis; 2024 May; 19(1):206. PubMed ID: 38769503
[TBL] [Abstract][Full Text] [Related]
5. Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma.
Welponer T; Weber DD; Trattner L; Tockner B; Aminzadeh-Gohari S; Leb-Reichl V; Kaufmann A; Zauner R; Wimmer M; Wally V; Felder TK; Strunk D; Koller U; Bauer JW; Kofler B; Guttmann-Gruber C; Piñon Hofbauer J
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):112-123. PubMed ID: 37669776
[TBL] [Abstract][Full Text] [Related]
6. Morphological and morphometric analysis of cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a retrospective study.
Filoni A; Cicco G; Lospalluti L; Maglietta A; Foti C; Annichiarico G; Resta L; Bonamonte D
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1707-1714. PubMed ID: 31692111
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa.
Rami A; Łaczmański Ł; Jacków-Nowicka J; Jacków J
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383666
[TBL] [Abstract][Full Text] [Related]
8. Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases.
Montaudié H; Chiaverini C; Sbidian E; Charlesworth A; Lacour JP
Orphanet J Rare Dis; 2016 Aug; 11(1):117. PubMed ID: 27544590
[TBL] [Abstract][Full Text] [Related]
9. New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma.
Nissinen L; Farshchian M; Riihilä P; Kähäri VM
Cell Tissue Res; 2016 Sep; 365(3):691-702. PubMed ID: 27411692
[TBL] [Abstract][Full Text] [Related]
10. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma.
Riihilä PM; Nissinen LM; Ala-Aho R; Kallajoki M; Grénman R; Meri S; Peltonen S; Peltonen J; Kähäri VM
J Invest Dermatol; 2014 Feb; 134(2):498-506. PubMed ID: 23938460
[TBL] [Abstract][Full Text] [Related]
11. Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.
Trefzer L; Hess ME; Scholten L; Technau-Hafsi K; Meiss F; Boerries M; Has C; Rafei-Shamsabadi D
Acta Derm Venereol; 2023 Jun; 103():adv4870. PubMed ID: 37338146
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the interplay between senescent dermal fibroblasts and cutaneous squamous cell carcinoma cell lines at different stages of tumorigenesis.
Toutfaire M; Dumortier E; Fattaccioli A; Van Steenbrugge M; Proby CM; Debacq-Chainiaux F
Int J Biochem Cell Biol; 2018 May; 98():113-126. PubMed ID: 29550586
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma.
Dayal JHS; Mason SM; Salas-Alanis JC; McGrath JA; Taylor RG; Mellerio JE; Blyth K; South AP; Inman GJ
Br J Dermatol; 2021 Apr; 184(4):697-708. PubMed ID: 32726455
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Patients With Multiple Cutaneous Squamous Cell Carcinomas: A 10-Year Single-Institution Cohort Study.
Levine DE; Karia PS; Schmults CD
JAMA Dermatol; 2015 Nov; 151(11):1220-5. PubMed ID: 26177278
[TBL] [Abstract][Full Text] [Related]
15. Periostin
Wei WF; Chen XJ; Liang LJ; Yu L; Wu XG; Zhou CF; Wang ZC; Fan LS; Hu Z; Liang L; Wang W
Mol Oncol; 2021 Jan; 15(1):210-227. PubMed ID: 33124726
[TBL] [Abstract][Full Text] [Related]
16. Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma.
Riihilä P; Viiklepp K; Nissinen L; Farshchian M; Kallajoki M; Kivisaari A; Meri S; Peltonen J; Peltonen S; Kähäri VM
Br J Dermatol; 2020 Mar; 182(3):658-670. PubMed ID: 31049937
[TBL] [Abstract][Full Text] [Related]
17. Pre-mRNA processing factor 3 enhances the progression of keratinocyte-derived cutaneous squamous cell carcinoma by regulating the JAK2/STAT3 pathway.
Zuo S; Li X; Bao W; Li S
Sci Rep; 2020 Jun; 10(1):8863. PubMed ID: 32483193
[TBL] [Abstract][Full Text] [Related]
18. Complement factor I promotes progression of cutaneous squamous cell carcinoma.
Riihilä P; Nissinen L; Farshchian M; Kivisaari A; Ala-Aho R; Kallajoki M; Grénman R; Meri S; Peltonen S; Peltonen J; Kähäri VM
J Invest Dermatol; 2015 Feb; 135(2):579-588. PubMed ID: 25184960
[TBL] [Abstract][Full Text] [Related]
19. Injury-Driven Stiffening of the Dermis Expedites Skin Carcinoma Progression.
Mittapalli VR; Madl J; Löffek S; Kiritsi D; Kern JS; Römer W; Nyström A; Bruckner-Tuderman L
Cancer Res; 2016 Feb; 76(4):940-51. PubMed ID: 26676755
[TBL] [Abstract][Full Text] [Related]
20. Podoplanin expression in cutaneous squamous cell carcinomas and its relationship to histopathological prognostic factors.
Gülseren D; Gököz Ö; Karahan S; Karaduman A
J Histotechnol; 2020 Sep; 43(3):147-152. PubMed ID: 32496961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
